BRIDGEWATER, N.J., Dec. 2, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Evercore ISI HealthCONx Conference in Coral Gables, Florida, on Wednesday, December 4, 2024, at 11:15 a.m. ET. Nasdaq 51st Investor Conference held in association with Morgan Stanle ...

Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for patients with serious diseases [4][5] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [4] - Insmed is recognized as one of the best employers in the biopharmaceutical industry, having been named the No. 1 Science Top Employer for four consecutive years [5] Upcoming Investor Conferences - Insmed will present at the Guggenheim's Inaugural Healthcare Innovation Conference in Boston on November 11, 2024, at 1:00 p.m. ET [1] - The company will also participate in the UBS Global Healthcare Conference in California on November 12, 2024, at 11:45 a.m. PT / 2:45 p.m. ET [2] - Additional presentations include the Wolfe Research Healthcare Conference in New York on November 20, 2024, at 8:00 a.m. ET and the Jefferies London Healthcare Conference on November 21, 2024, at 8:30 a.m. GT / 3:30 a.m. ET [2] Webcast Information - The events will be webcast live and accessible via the investor relations section of Insmed's website [3] - Webcasts will be archived for 30 days following the live events [3]

Core Insights - Insmed reported a third-quarter 2024 loss of $1.27 per share, which was wider than the Zacks Consensus Estimate of a loss of $1.19, and compared to a loss of $1.11 per share in the same quarter last year [1] - Total revenues for the quarter were $93.4 million, reflecting an 18% year-over-year increase, and were in line with the Zacks Consensus Estimate [1] - The company's shares declined over 4% following the earnings miss [1] Revenue Generation - All revenues in the reported quarter were generated from Arikayce, the company's only marketed drug, which treats refractory mycobacterium avium complex (MAC) lung disease [4] - Arikayce sales increased by 13% to $66.9 million in the United States, 31% to $21.0 million in Japan, and 45% to $5.6 million in Europe and the rest of the world [5] Expenses - Research and development (R&D) expenses rose 38% year over year to $150.8 million, while selling, general and administrative (SG&A) expenses increased by 31% to $118.9 million [6] Cash Position - As of September 30, 2024, Insmed had cash, cash equivalents, and marketable securities of approximately $1.5 billion, up from $1.2 billion as of June 30, 2024, due to net proceeds of $371 million from the company's equity program [7] Guidance - Management maintained its sales guidance for Arikayce for the full year, expecting product sales to be between $340 million and $360 million, indicating a 15% year-over-year growth at the midpoint [8] Pipeline Updates - Insmed plans to meet with the FDA to discuss the potential for accelerated approval to expand Arikayce's label for all patients with MAC lung infection [9] - The total addressable market (TAM) for refractory MAC is estimated at around 30,000 patients, which could increase to approximately 275,000 patients if Arikayce is approved for newly infected patients [10] - Insmed is on track to submit a regulatory filing for brensocatib in bronchiectasis by the end of the year, with a potential commercial launch in mid-2025 [11] - The company is also evaluating brensocatib in chronic rhinosinusitis and plans to initiate a mid-stage study for HS indication before the end of 2024 [12] - Top-line data from a mid-stage study of TPIP in pulmonary arterial hypertension is expected in the second half of 2025 [13]

Core Insights - Insmed reported $93.43 million in revenue for Q3 2024, marking an 18.2% year-over-year increase, with an EPS of -$1.27 compared to -$1.10 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of $93.31 million by 0.12%, while the EPS fell short of the consensus estimate of -$1.19 by 6.72% [1] Revenue Breakdown - Revenue from Japan was $20.98 million, below the estimated $24.10 million, but showed a year-over-year increase of 30.9% [3] - Revenue from Europe and the rest of the world reached $5.57 million, slightly above the $5.45 million estimate, reflecting a 45.3% year-over-year growth [3] - U.S. revenue was $66.87 million, surpassing the average estimate of $64.70 million, with a year-over-year increase of 13% [3] Stock Performance - Insmed's shares have declined by 3.7% over the past month, contrasting with a 1% increase in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]

Insmed (INSM) came out with a quarterly loss of $1.27 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $1.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -6.72%. A quarter ago, it was expected that this biopharmaceutical developing inhaled treatments for patients battling rare lung diseases would post a loss of $1.22 per share when it actually produced a loss of $1.94, delivering a ...

Exhibit 99.1 1 Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023— —NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025— —Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awa ...

—ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $93.4 Million for the Third Quarter of 2024, Reflecting 18% Growth Over the Third Quarter of 2023——NDA Submission for Brensocatib in Bronchiectasis Remains on Track for the Fourth Quarter of 2024 with Potential U.S. Launch Still Expected in Mid-2025——Expanded U.S. Sales Force is Now Fully Deployed; Focusing on Bronchiectasis Disease-State Awareness and Supporting the Growth of ARIKAYCE Prior to the Anticipated Launch of Brensocatib——Ends ...

Wall Street analysts forecast that Insmed (INSM) will report quarterly loss of $1.19 per share in its upcoming release, pointing to a year-over-year decline of 8.2%. It is anticipated that revenues will amount to $93.31 million, exhibiting an increase of 18% compared to the year-ago quarter. The consensus EPS estimate for the quarter has undergone an upward revision of 0.8% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their ini ...

Core Insights - Insmed Incorporated held its third annual Global Day of Good, with over 1,000 employees volunteering across the U.S., Europe, and Japan, marking the largest participation to date [1][2] - The activities focus on improving health, education, and human services, benefiting more than 40 organizations globally [1][2] - Insmed emphasizes a culture of community support, with various volunteer projects including preparing kits for pediatric cancer patients and revitalizing community centers [2][3] Company Overview - Insmed is a global biopharmaceutical company dedicated to delivering first- and best-in-class therapies for serious diseases, with a diverse portfolio of approved and investigational medicines [4] - The company is advancing programs primarily in pulmonary and inflammatory conditions, including a therapy approved in the U.S., Europe, and Japan for chronic lung disease [4] - Insmed is recognized as a top employer in the biopharmaceutical industry, having been named the No. 1 Science Top Employer for three consecutive years [5]

Core Points - Insmed Incorporated will release its third-quarter 2024 financial results on October 31, 2024 [1] - A conference call for investors will be held on the same day at 8:00 a.m. ET to discuss the financial results and provide a business update [2] - The conference call will be accessible via phone and will also be webcast live on the company's website [2] Company Overview - Insmed is a global biopharmaceutical company focused on delivering first- and best-in-class therapies for serious diseases [4] - The company has a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [4] - Insmed is recognized as one of the best employers in the biopharmaceutical industry, having been ranked as the No. 1 Science Top Employer for three consecutive years [5]